Poly ADP‐ribose polymerase (PARP) inhibitors are novel targeted drugs, which have recently been approved to treat advanced ovarian cancer patients carrying BRCA1/2 mutations (Shi et al., 2017). Here, BRCA1 is linked to ovarian cancer.